SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability

SETD2 loss of function is a recurrent event in advanced‐phase chronic myeloid leukemia and contributes to genomic instability

Abstract The SETD2 tumour suppressor encodes a histone methyltransferase that specifically trimethylates histone H3 on lysine 36 (H3K36me3), a key histone mark implicated in the maintenance of genomic integrity among other functions. We found that SETD2 protein deficiency, mirrored by H3K36me3 defic...

Full description

Saved in:
Bibliographic Details
Main Authors: Manuela Mancini, Sara De Santis, Cecilia Monaldi, Fausto Castagnetti, Miriam Iezza, Alessandra Iurlo, Daniele Cattaneo, Sara Galimberti, Marco Cerrano, Isabella Capodanno, Massimiliano Bonifacio, Maura Rossi, Claudio Agostinelli, Manja Meggendorfer, Torsten Haferlach, Michele Cavo, Gabriele Gugliotta, Simona Soverini
Format: Article
Language:English
Published: Wiley 2025-04-01
Series:Clinical and Translational Medicine
Subjects:
Aurora kinase A
genomic instability
H3K36me3
MDM2
SETD2
Online Access:https://doi.org/10.1002/ctm2.70163
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ctm2.70163

Similar Items